NAS:XENT (USA) Also trade in: Germany

Intersect ENT Inc

$ 20.47 0 (0%)
Volume: 310,077 Avg Vol (1m): 482,230
Market Cap $: 639.61 Mil Enterprise Value $: 542.03 Mil
P/E (TTM): 0.00 P/B: 5.32
Earnings Power Value -0.68
Net Current Asset Value 3.59
Tangible Book 3.84
Projected FCF -5.73
Median P/S Value 32.1
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9.8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt range over the past 10 years
Min: 1.03, Med: 10000, Max: 10000
Current: 10000
1.03
10000
Equity-to-Asset 0.85
Equity-to-Asset range over the past 10 years
Min: -5.85, Med: 0.88, Max: 0.93
Current: 0.85
-5.85
0.93
Interest Coverage No Debt
N/A
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 20.12
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC -166.53%
WACC 7.41%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -27.08
Operating Margin range over the past 10 years
Min: -281.17, Med: -43.74, Max: -18.28
Current: -27.08
-281.17
-18.28
Net Margin % -24.99
Net Margin range over the past 10 years
Min: -279.12, Med: -43.24, Max: -16.99
Current: -24.99
-279.12
-16.99
ROE % -22.98
ROE range over the past 10 years
Min: -28.94, Med: -19.93, Max: -14.13
Current: -22.98
-28.94
-14.13
ROA % -20.10
ROA range over the past 10 years
Min: -226.44, Med: -25.66, Max: -12.33
Current: -20.1
-226.44
-12.33
ROC (Joel Greenblatt) % -169.42
ROC (Joel Greenblatt) range over the past 10 years
Min: -939.32, Med: -429.15, Max: -134.11
Current: -169.42
-939.32
-134.11
3-Year Total Revenue Growth Rate 20.80
3-Year Revenue Growth Rate range over the past 10 years
Min: -26.2, Med: 7.1, Max: 39.2
Current: 15
-26.2
39.2
3-Year Total EBITDA Growth Rate 4.00
3-Year EBITDA Growth Rate range over the past 10 years
Min: 4.2, Med: 18.7, Max: 60.5
Current: 8.6
4.2
60.5
3-Year EPS w/o NRI Growth Rate 9.30
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 8.7, Med: 19.5, Max: 60.4
Current: 9.3
8.7
60.4

» XENT's 30-Y Financials

Financials (Next Earnings Date: 2019-08-01)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:XENT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Devices » Medical Devices    NAICS : 339112    SIC : 3841
Compare OSTO:ARJO B NAS:OFIX SZSE:300298 TSE:6960 NAS:TCMD XTER:DRW8 NAS:BABY NYSE:CRY SHSE:603387 SZSE:300326 HKSE:01302 SZSE:300238 SHSE:600587 NAS:SWAV NAS:AXGN XTER:SBS NYSE:INSP SZSE:002317 NAS:SILK NAS:CSII
Traded in other countries 7IN.Germany
Address 1555 Adams Drive, Menlo Park, CA, USA, 94025
Intersect ENT Inc is a drug device company that develops products for patients with ear, nose, and throat conditions. The firm's key commercial products are the Propel brand of steroid-releasing implants, which are used in patients undergoing surgery for chronic sinusitis. These implants are placed into the ethmoid sinuses after surgery and are designed to expand and hold open the surgically enlarged sinus while releasing an anti-inflammatory steroid. After roughly 30 days, the implant is fully absorbed into the body. Intersect ENT generates the vast majority of its revenue in the United States.

Ratios

Current vs industry vs history
PB Ratio 5.32
PB Ratio range over the past 10 years
Min: 2.37, Med: 6.94, Max: 12.64
Current: 5.32
2.37
12.64
PS Ratio 5.64
PS Ratio range over the past 10 years
Min: 3.41, Med: 8.89, Max: 14.41
Current: 5.64
3.41
14.41
EV-to-EBIT -18.13
EV-to-EBIT range over the past 10 years
Min: -66.5, Med: -26.7, Max: -6.4
Current: -18.13
-66.5
-6.4
EV-to-EBITDA -19.70
EV-to-EBITDA range over the past 10 years
Min: -73.1, Med: -27.65, Max: -6.7
Current: -19.7
-73.1
-6.7
EV-to-Revenue 4.88
EV-to-Revenue range over the past 10 years
Min: 2.1, Med: 7.7, Max: 14.7
Current: 4.88
2.1
14.7
Current Ratio 6.53
Current Ratio range over the past 10 years
Min: 1.28, Med: 8.7, Max: 14.68
Current: 6.53
1.28
14.68
Quick Ratio 5.84
Quick Ratio range over the past 10 years
Min: 0.95, Med: 8.33, Max: 14.37
Current: 5.84
0.95
14.37
Days Inventory 181.81
Days Inventory range over the past 10 years
Min: 79.99, Med: 130.8, Max: 181.81
Current: 181.81
79.99
181.81
Days Sales Outstanding 57.29
Days Sales Outstanding range over the past 10 years
Min: 57.29, Med: 67.96, Max: 85.49
Current: 57.29
57.29
85.49
Days Payable 71.07
Days Payable range over the past 10 years
Min: 56.67, Med: 80.07, Max: 102.17
Current: 71.07
56.67
102.17

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -2.80
3-Year Share Buyback Rate range over the past 10 years
Min: -204.3, Med: -13.1, Max: -2.8
Current: -2.8
-204.3
-2.8

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 5.33
Price-to-Tangible-Book range over the past 10 years
Min: 3.03, Med: 7.12, Max: 12.29
Current: 5.33
3.03
12.29
Price-to-Median-PS-Value 0.64
Price-to-Median-PS-Value range over the past 10 years
Min: 0.49, Med: 1.04, Max: 1.44
Current: 0.64
0.49
1.44
Earnings Yield (Joel Greenblatt) % -5.46
Earnings Yield (Greenblatt) range over the past 10 years
Min: -15.7, Med: -3.7, Max: -1.5
Current: -5.46
-15.7
-1.5

More Statistics

Revenue (TTM) (Mil) $ 110.42
EPS (TTM) $ -0.9
Beta 0.81
Volatility % 37.04
52-Week Range $ 20.14 - 35.87
Shares Outstanding (Mil) 31.25

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y